
Rallybio Corp
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Rallybio Corp is a clinical-stage biotechnology company developing therapies for severe and rare diseases, including programs targeting fetal and neonatal alloimmune thrombocytopenia and other rare hematologic and pediatric conditions. The company is headquartered in New Haven, Connecticut, and trades on Nasdaq under the ticker RLYB.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Lieber Jonathan IChief Financial Officer | Sell | $10K | 599at $16.04 | Oct 27, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable RLYB activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.